To determine the change from baseline to post-treatment values in HR-positive, HER2-negative invasive lobular carcinoma tissue derived from postmenopausal women awaiting definitive surgery or further treatment.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Kristalyn Gallagher
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Breast)
16-2022